A Cleavage Enzyme-Cytometric Bead Array Provides Biochemical Profiling of Resistance Mutations in HIV-1 Gag and Protease

被引:10
作者
Breuer, Sebastian [1 ]
Sepulveda, Homero [2 ]
Chen, Yu [2 ]
Trotter, Joseph [2 ]
Torbett, Bruce E. [1 ]
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[2] BD Biosci, San Diego, CA 92121 USA
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; PROCESSING SITES; DRUG-RESISTANCE; VIRAL FITNESS; AMINO-ACID; IN-VIVO; INHIBITORS; VARIANTS; POLYMORPHISM; SELECTION;
D O I
10.1021/bi200031m
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Most protease-substrate assays rely on short, synthetic peptide substrates consisting of native or modified cleavage sequences. These assays are inadequate for interrogating the contribution of native substrate structure distal to a cleavage site that influences enzymatic cleavage or for inhibitor screening of native substrates. Recent evidence from HIV-1 isolates obtained from individuals resistant to protease inhibitors has demonstrated that mutations distal to or surrounding the protease cleavage sites in the Gag substrate contribute to inhibitor resistance. We have developed a protease substrate cleavage assay, termed the cleavage enzyme cytometric bead array (CE-CBA), which relies on native domains of the Gag substrate containing embedded cleavage sites. The Gag substrate is expressed as a fluorescent reporter fusion protein, and substrate cleavage can be followed through the loss of fluorescence utilizing flow cytometry. The CE-CBA allows precise determination of alterations in protease catalytic efficiency (k(cat)/K(M)) imparted by protease inhibitor resistance mutations in protease and/or gag in cleavage or noncleavage site locations in the Gag substrate. We show that the CE-CBA platform can identify HIV-1 protease present in cellular extractions and facilitates the identification of small molecule inhibitors of protease or its substrate Gag. Moreover, the CE-CBA can be readily adapted to any enzyme substrate pair and can be utilized to rapidly provide assessment of catalytic efficiency as well as systematically screen for inhibitors of enzymatic processing of substrate.
引用
收藏
页码:4371 / 4381
页数:11
相关论文
共 40 条
[21]   Novel trends in high-throughput screening [J].
Mayr, Lorenz M. ;
Bojanic, Dejan .
CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (05) :580-588
[23]   A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance [J].
Muzammil, S ;
Ross, P ;
Freire, E .
BIOCHEMISTRY, 2003, 42 (03) :631-638
[24]   Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1 [J].
Myint, L ;
Matsuda, M ;
Matsuda, Z ;
Yokomaku, Y ;
Chiba, T ;
Okano, A ;
Yamada, K ;
Sugiura, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :444-452
[25]  
NAGAI T, 2001, NATURE, V20, P1585
[26]   New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors [J].
Nalam, Madhavi N. L. ;
Schiffer, Celia A. .
CURRENT OPINION IN HIV AND AIDS, 2008, 3 (06) :642-646
[27]   Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy [J].
Nijhuis, M ;
Schuurman, R ;
de Jong, D ;
Erickson, J ;
Gustchina, E ;
Albert, J ;
Schipper, P ;
Gulnik, S ;
Boucher, CAB .
AIDS, 1999, 13 (17) :2349-2359
[28]   A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism [J].
Nijhuis, Monique ;
van Maarseveen, Noortje M. ;
Lastere, Stephane ;
Schipper, Pauline ;
Coakley, Eoin ;
Glass, Barbel ;
Rovenska, Mirka ;
de Jong, Dorien ;
Chappey, Colombe ;
Goedegebuure, Irma W. ;
Heilek-Snyder, Gabrielle ;
Dulude, Dominic ;
Cammack, Nick ;
Brakier-Gingras, Lea ;
Konvalinka, Jan ;
Parkin, Neil ;
Kraeusslich, Hans-Georg ;
Brun-Vezinet, Francoise ;
Boucher, Charles A. B. .
PLOS MEDICINE, 2007, 4 (01) :152-163
[29]   Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease [J].
Pettit, SC ;
Henderson, GJ ;
Schiffer, CA ;
Swanstrom, R .
JOURNAL OF VIROLOGY, 2002, 76 (20) :10226-10233
[30]   How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease [J].
Prabu-Jeyabalan, M ;
Nalivaika, E ;
Schiffer, CA .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 301 (05) :1207-1220